. Author manuscript; available in PMC: 2015 Mar 9.

Published in final edited form as: Biol Blood Marrow Transplant. 2010 Jan 29;16(4):555–559. doi: 10.1016/j.bbmt.2009.12.004

Table 3.

Outcomes of 14 Patients with Myelofibrosis and Leukemic Transformation Treated with Allogeneic Stem Cell Transplantation

Primary engraftment (%)^*	100%
Engraftment (median, range)
Day to ANC 500 (N = 14)	13 (8-21)
Days to platelet count 20,000 (N = 11)	21.5 (13-40)
Chimerism at day 30 by PCR^* (N = 14)
100%	11
85%-99%	2
Not tested	1
Median follow-up survivors, months (range)	31 (10-127)
aGVHD, n
Grade II-IV	5
Grade III-IV	2
cGVHD, n
All grades	5
Extensive	2
Complete remission after transplant, n	14
Disease progression
n (% CI)	4 (38%) (16-89)^†
NRM, Overall
n (% CI)	4 (29%) (12-65)^†
PFS, Overall
n (% CI)	6 (33%) (7-63)^†
OS, Overall
n (% CI)	7 (49%) (22-72)^†

ANC indicates absolute neutrophil count; PCR, polymerase chain reaction; aGVHD, acute graft-versus-host-disease; cGVHD, chronic graft-versus-host disease; NRM, nonrelapse mortality; PFS, progression-free survival; OS, overall survival; CI, cumulative incidence.

Donor myeloid and T cells.

^†

95% Confidence interval.